|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 676.69 USD | -0.33% |
|
+1.83% | -12.33% |
| 16/07 | Merck gets US FDA nod for first-in-its-class oral cholesterol drug | RE |
| 15/07 | Alnylam Initiates Mid-Stage Study of Mivelsiran in Down Syndrome-Associated Alzheimer's | MT |
| Market Cap | 68.85B 60.16B 55.52B 51.17B 96.45B 6,630B 98.59B 664B 261B 3,247B 259B 253B 11,178B | P/E 2026 * |
17.8x | P/E 2027 * | 14.3x |
|---|---|---|---|---|---|
| Enterprise Value | 61.02B 53.33B 49.21B 45.36B 85.49B 5,877B 87.39B 588B 231B 2,878B 229B 224B 9,908B | EV / Sales 2026 * |
3.85x | EV / Sales 2027 * | 3.31x |
| Free-Float |
72.33% | Yield 2026 * |
0.58% | Yield 2027 * | 0.66% |
Last Transcript: Regeneron Pharmaceuticals, Inc.
| 1 day | -0.33% | ||
| 1 week | +1.83% | ||
| Current month | +8.52% | ||
| 1 month | +10.94% | ||
| 3 months | -9.84% | ||
| 6 months | -7.69% | ||
| Current year | -12.33% |
| 1 week | 648.66 |  | 691.13 |
| 1 month | 594.9 | | 691.13 |
| Current year | 591.52 | | 821.11 |
| 1 year | 541 | | 821.11 |
| 3 years | 476.49 | | 1,211.2 |
| 5 years | 476.49 | | 1,211.2 |
| 10 years | 271.37 | | 1,211.2 |
| Manager | Title | Age | Since |
|---|---|---|---|
| President | 66 | 01/01/2001 | |
| Chief Executive Officer | 73 | 08/01/1988 | |
| Director of Finance/CFO | 55 | 05/02/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 73 | 09/06/2023 | |
Michael Brown
BRD | Director/Board Member | 85 | 01/06/1991 |
Joseph Goldstein
BRD | Director/Board Member | 85 | 01/06/1991 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 2/7/26 | Sell | Director | -200 | 0.0002% | ||
| 1/5/26 | Sell | Director | -100 | 0.0001% | ||
| 1/4/26 | Sell | Director | 100 | 0.0001% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.33% | +1.83% | +24.73% | -6.86% | 68.85B | |
| +0.67% | +0.93% | +36.86% | +197.49% | 52.13B | |
| +0.94% | +39.60% | +39.60% | +39.60% | 43.46B | |
| +1.12% | +0.35% | -52.09% | -53.39% | 41.24B | |
| -1.40% | +3.43% | +64.81% | -25.41% | 30.41B | |
| -2.11% | -9.45% | +97.76% | -49.58% | 24.53B | |
| +0.51% | +0.46% | +72.78% | +90.09% | 23.42B | |
| -5.57% | -0.84% | -0.11% | +182.38% | 19.75B | |
| -0.86% | -1.99% | +70.03% | +117.01% | 16.57B | |
| +1.34% | -5.25% | +74.97% | +150.25% | 15.95B | |
| Average | -0.57% | -1.25% | +42.93% | +64.16% | 33.63B | |
| Weighted average by Cap. | -0.26% | -0.31% | +34.57% | +51.74% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 15.86B 13.86B 12.79B 11.79B 22.22B 1,527B 22.71B 153B 60.13B 748B 59.56B 58.25B 2,575B | 17.64B 15.42B 14.23B 13.12B 24.72B 1,699B 25.27B 170B 66.89B 832B 66.26B 64.81B 2,865B |
| Net income | 3.99B 3.49B 3.22B 2.97B 5.59B 384B 5.71B 38.45B 15.12B 188B 14.98B 14.65B 648B | 5.03B 4.39B 4.05B 3.74B 7.04B 484B 7.2B 48.45B 19.05B 237B 18.88B 18.46B 816B |
| Net Debt | -7.82B -6.84B -6.31B -5.81B -10.96B -753B -11.2B -75.4B -29.66B -369B -29.38B -28.73B -1,270B | -10.51B -9.19B -8.48B -7.81B -14.73B -1,012B -15.06B -101B -39.86B -496B -39.48B -38.62B -1,707B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 17/07/26 | USD 676.69 | -0.33% | 648,400 |
| 16/07/26 | USD 678.94 | +2.18% | 730,245 |
| 15/07/26 | USD 664.45 | +1.27% | 555,419 |
| 14/07/26 | USD 656.12 | -1.05% | 477,991 |
| 13/07/26 | USD 663.09 | -0.22% | 606,304 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- REGN Stock
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition